Figure 8.

Fasciola hepatica FABP1 induces a type 2 immune response in adipose tissue but without affecting metabolic homeostasis in obese mice Mice were fed a high-fat diet (HFD) for a period of 12 weeks and then received intraperitoneal injections of 25 µg recombinant fhFABP1 (orange squares/bars) or vehicle (PBS, black squares/bars) every 3 days for 4 weeks (A) Body weight was monitored throughout the supplementation period (B) At week 4, body composition was determined (C) After sacrifice, the weights of the liver and eWAT were measured (D) The number of eWAT total leukocytes (E), CD4⁺ T cells (F), eosinophils (I) and total macrophages (J), together with the percentage of CD44⁺, IL-5⁺, IFNγ⁺ CD4⁺ T cells (G) and the YM1 and RELMα mean expression on macrophages (K) were determined by flow cytometry The IL-5⁺-on-IFNγ⁺ ratio was calculated (H) At week 4, fasting blood glucose levels were measured (L) At week 3-4, whole-body insulin sensitivity (M) and glucose tolerance (N) were performed and the respective AUC was calculated Results are expressed as mean ± SEM ^#P ≤ 005 vs HFD (n=5-6 mice per group).